Comparative Pharmacology
Head-to-head clinical analysis: KEFLIN versus ROCEPHIN KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFLIN versus ROCEPHIN KIT.
KEFLIN vs ROCEPHIN KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation, leading to cell lysis.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis and death.
1-2 g IV/IM every 4-6 hours; maximum 12 g/day.
Adult: 1-2 g IV or IM every 24 hours. Maximum 4 g/day for severe infections.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (normal renal function); prolonged to 2-3 hours in anuria. Clinically, dosing every 6 hours is recommended.
Terminal half-life 6-9 hours in healthy adults; prolonged to 12-15 hours in elderly and up to 30 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 70-80% unchanged via glomerular filtration and tubular secretion; biliary: minimal (<5%); fecal: <1%.
Renal (33-67% unchanged), biliary (40-50% as active drug and metabolites), fecal (minor).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic